|
||||||||||||||||
|
||||||||||||||||
|
||||||||||||||||
|
| ||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||
Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter.
Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.
Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.
OCR for page 19
B
Workshop Agenda
Alzheimer’s Diagnostic Criteria Validation: Exploration of Next Steps
A Workshop
Monday, July 18, 2011
2011 International Conference on Alzheimer’s Disease
10:30 a.m. Session Overview
WILLIAM THIES
Chief Medical and Scientific Officer
Alzheimer’s Association
GABRIELLE SILVER
Global Strategic Marketing Leader, Neurology
GE Healthcare
10:40 a.m. Updating the Diagnostic Criteria: Two Guidelines
• eview the primary updates to the criteria
R
• xamine the similarities and differences between the
E
National Institute of Aging/Alzheimer’s Association and
International Working Group guidelines
• iscuss the role the new criteria will have in a clinical
D
setting
PHILLIP SCHELTENS
Director
Alzheimer Center
Vrije Universiteit Medical Center
19
OCR for page 20
20 ALZHEIMER’S DIAGNOSTIC GUIDELINES
11:05 a.m. Validating the New Criteria: Lessons Learned from
Cardiovascular Disease and Cholesterol
• xplore challenges and lessons learned in the validation
E
of cholesterol as a biomarker
• dentify lessons learned that could be applied in the
I
validation of AD guidelines
ROBERT MAHLEY
Senior Investigator
Gladstone Institute of Cardiovascular Disease and
Neurological Disease
University of California, San Francisco
11:45 a.m. Panel Discussion: Identifying Principle Strategies for
Validation of New Criteria
• dentify a set of core principles that can be used to
I
validate the newly proposed diagnostic criteria guidelines
for symptomatic pre-dementia and dementia AD
• iscuss next steps and strategies for moving forward
D
o Examine the types of studies needed, their design and
execution
WILLIAM THIES, Moderator
Chief Medical and Scientific Officer
Alzheimer’s Association
MONIQUE BRETELER
Professor
German Center for Neurodegenerative Diseases
DAVID BROOKS
Professor, Imperial College
Chief Medical Officer, GE Healthcare
CHARLES DeCARLI
Director
Alzheimer’s Disease Center
University of California, Davis
OCR for page 21
21
APPENDIX B
ROBERT MAHLEY
Senior Investigator
Gladstone Institute of Cardiovascular Disease and
Neurological Disease
University of California, San Francisco
12:30 p.m. ADJOURN
OCR for page 22
